Dynavax Presents New Analysis Of TOLAMBA(TM) Data At ACAAI Meeting

Dynavax Technologies Corporation (Nasdaq: DVAX) presented yesterday a detailed analysis of data from the company’s large-scale DARTT (SAR09) trial evaluating TOLAMBA(TM), a novel therapy for ragweed allergic rhinitis. The data were reported yesterday at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Dallas, TX. [click link for full article]

More: continued here

Filed under: Allergies on November 18th, 2007